期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 35, 期 -, 页码 193-195出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2019.08.006
关键词
Multiple sclerosis; Ankylosing spondylitis; Secukinumab; TNF inhibitors; Clinical report
The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1 kappa monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据